From Our Perspective - 340B Matters
15581
page-template,page-template-blog-large-image,page-template-blog-large-image-php,page,page-id-15581,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-9.1.3,wpb-js-composer js-comp-ver-4.11.1,vc_responsive

From Our Perspective

18 Nov Biden Transition Team Must Address the 340B Drug Discount Program

By 340B Matters America’s healthcare first responders are girding for the looming winter surge in the pandemic. Amid the stress and strain, the 340B Drug Discount Program is a lifeline that helps safety-net providers care for underserved patients across the country. Congress designed the 340B program nearly...

Read More

29 Oct Ways to Improve 340B Drug Discount Program

By 340B Matters Senator Lamar Alexander (R-Tenn.) and Rep. Greg Walden (R-Ore.) have asked stakeholders in the 340B Drug Discount Program to submit ideas on how it can be improved. It’s a request that both pharmaceutical manufacturers and safety-net healthcare providers should take seriously. With a few updates, the...

Read More

13 Oct JAMA Study: 340B Does Not Raise Drug Prices

By 340B Matters The drug industry and its surrogates have contended for years that the 340B Drug Discount Program somehow raises drug prices overall. It has argued that discounts provided under 340B to safety-net hospitals and clinics are offset by manufacturers when selling those same medicines at...

Read More

08 Oct Let the Lawsuits Begin

By 340B Matters The drug industry is spoiling for a legal fight over the 340B Drug Discount Program. Safety-net hospitals and clinics should give them one by suing over clear breaches of federal law. By turns peremptory and obnoxious, Eli Lilly, AztraZeneca, Merck and Sanofi have unilaterally...

Read More

28 Sep HHS and Congress Slam Big Pharma’s Actions Against 340B

By 340B Matters In response to Big Pharma’s recent unprecedented attacks on the 340B Drug Discount Program, Congress and the Department of Health and Human Services have put the manufacturers on notice that their actions may be formally rebuked by the federal government. HHS General Counsel Robert...

Read More

14 Sep Azar Selling Out Healthcare First Responders to Please Big Pharma

By 340B Matters Safety-net healthcare providers and first responders on the front lines of a global pandemic are facing an illegal campaign from drug companies to raise drug prices. These heroes have asked Health and Human Services Secretary Alex Azar to intervene. His silence is deafening. Azar is...

Read More

31 Aug HRSA Must Enforce 340B Law

By 340B Matters Setting rules without enforcement? That’s ridiculous. But that’s just what’s happening with the 340B Drug Discount Program as the federal agency that oversees it has decided to walk off the job. The Health Resources and Services Agency has been the arbiter of the 340B program for almost 30 years....

Read More

20 Aug Astra Zeneca to Overcharge Safety-Net Healthcare Providers

By 340B Matters Mega drugmaker AstraZeneca has decided now is the ideal time to overcharge safety-net healthcare providers valiantly fighting the global pandemic. The company announced, starting October 1, it will stop offering lower pricing to America’s safety-net providers participating in the 340B Drug Discount Program if...

Read More

07 Aug 340B Program Faces Big Pharma Attacks, HRSA Inaction

By 340B Matters Just as safety-net healthcare providers face historic budget shortfalls due to the pandemic, Big Pharma has launched an attack on the 340B Drug Discount Program while the federal agency overseeing it has suspiciously turned away. Eli Lilly, Merck and Sanofi have unilaterally undermined the...

Read More

23 Jul Drug Companies Mount Unilateral Attacks on 340B Program

By 340B Matters Big Pharma has spent years and millions of dollars in an unsuccessful campaign to destroy a program that strengthens our nation’s public health system at no cost to taxpayers: the 340B Drug Discount Program. Because of strong bi-partisan support for 340B in Congress,...

Read More